Back to Search
ALBERT LOBUGLIO, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1003175399Individual
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
10824(AL)
Research & Publications (20)
Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.
PMID 19574765·Int J Gynecol Cancer·2009
8-other
A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae.
PMID 18199606·J Nucl Med·2008
8-other
Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
PMID 18381960·Clin Cancer Res·2008
7-preclinical
Hedgehog pathway expression in heterogeneous pancreatic adenocarcinoma: implications for the molecular analysis of clinically available biopsies.
PMID 18043287·Diagn Mol Pathol·2007
8-other
Brief overview of preclinical and clinical studies in the development of intraperitoneal radioimmunotherapy for ovarian cancer.
PMID 17875801·Clin Cancer Res·2007
6-review
Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.
PMID 17303227·Gynecol Oncol·2007
8-other
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.
PMID 17786709·Leuk Lymphoma·2007
8-other
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.
PMID 18089714·Mol Cancer Ther·2007
4-observational
Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function.
PMID 16951164·Cancer Res·2006
8-other
Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy.
PMID 17229341·Clin Lymphoma Myeloma·2006
5-case
A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma.
PMID 17257071·Cancer Biother Radiopharm·2006
3-trial
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma.
PMID 16436637·J Mol Diagn·2006
7-preclinical
Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity.
PMID 17257070·Cancer Biother Radiopharm·2006
8-other
Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma.
PMID 15930353·Clin Cancer Res·2005
3-trial
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein.
PMID 16114986·Cancer Biother Radiopharm·2005
3-trial
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
PMID 16248762·Cancer Biother Radiopharm·2005
3-trial
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
PMID 16248766·Cancer Biother Radiopharm·2005
7-preclinical
Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
PMID 16299250·Clin Cancer Res·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1802 6TH AVE S, NP 2556
BIRMINGHAM, AL 35233 - Phone
- (205) 934-5077
Quick Facts
- NPI
- 1003175399
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile